Sorrento Therapeutics and Karolinska Institutet researchers collaborate on NK cell therapy

Published: 11 June 2021

The new agreement aims to produce novel  cell-based therapies using natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs). 

US-based Sorrento and the NextGenNK Competence Center-associated research groups at the Department of Medicine, Karolinska Institutet (KI), Sweden, have entered into a research collaboration with the vision of bringing off-the-shelf NK cell-based cancer treatments to patients. 

Sorrento will bring its chimeric antigen receptor (CAR) and dimeric antigen receptor (DAR) technologies to the collaboration, and will fund translational validation. The KI researchers will establish iPSC-derived NK-based therapeutic candidates using Sorrento’s technology, and multiple candidates will be developed and tested.

“It is a privilege to continue and extend our collaborative work with the distinguished KI faculty. We are proud to contribute our technologies to produce new optimized off-the-shelf adoptive NK cell immunotherapies," said Henry Ji, Chairman and CEO of Sorrento, in a press release. "Our partnership with KI combines our know-how with the expertise of a world-renowned institution in the field of NK cell therapy. These types of partnerships are essential in advancing medicine and bringing new solutions to cancer patients in need.”